Maybe go back to the previous ASX announcement dated 21-05-2020
Mark Diamond, CEO of Antisense Therapeutics said: “Our focus is to continue planning and to methodically and efficiently move our DMD program through Phase IIb in Europe. There is great interest in the DMD space. As we gain further certainty from the regulatory process on the parameters of the next trial, which may lead to early market approval, we will assess funding and trial management options and also engage in discussions with interested potential partners ahead of commencement of Phase IIb. This will allow the Company to consider the most advantageous way to proceed with the pivotal trial on its own or with a partner. Potential partners’ input into the trial program may also be beneficial for future commercialisation plans........”.
As Mark said: "We've got a bit of time to think over the options."
If you also can recall.... In 2018, Mark also mentioned that it’s DMD market that can make them money...they would even be willing to commercialise the drug themselves if it comes through Phase 2 trials well, rather than licensing it out.
With the new Chairman on board ..Anything is possible before the next quarter...we wait patiently..
ANP Price at posting:
20.5¢ Sentiment: Buy Disclosure: Held
